Daiichi Sankyo - Downside Limited from Here

Daiichi Sankyo (4568 JP) Releases Phase I Data for DS-8201 at ESMO 2017

Did AstraZeneca Really Bid for Daiichi Sankyo, Did Daiichi Sankyo Really Turn Them Down?

Daiichi Sankyo (4568) - Is Luck Running Out?

Japan TMT Analyst

Pelham Smithers

Market Intel on Asian Tech with a Japan focus

Pelham Smithers Associates

Founded in 2009, Pelham Smithers Associates (PSA) provides market intelligence on Asian technology, focusing in particular on Japan. The industries covered by our team of specialists are: consumer electronics, telecomms, pharmaceuticals, internet, electronic parts and materials, automotive technology, retail and capital goods. 

Research is provided by the following:
Pelham Smithers: Macro, consumer electronics, telecoms & pharma
Joel Scheiman: Electronics materials / components
Julie Boote: Autos
Will Nestuk: Capital goods, machinery & transportation equipment parts
Thao Nguyen: eCommerce, internet content, marketing & advertising

Equity Bottom-Up

<p>Last week, <strong><a href="https://www.smartkarma.com/entities/3014" target="_blank" data-smartkarma-citation="entities:3014:1">Daiichi Sankyo (4568 JP)</a></strong> announced that its highly promising anti-cancer drug, DS-8201, has a second pivotal trial, this time moving to Phase II for gastric cancer (GC). Earlier in the year, DS-8201 moved to Phase II for its key indication for metastatic breast cancer (mBC). Since publication of the disappointing clinical trial data for mirogabalin, DS-8201 has taken on massive importance for DSK. This is not just because it is now the drug with the most upside potential in DSK’s…</p>

Last week, Daiichi Sankyo (4568 JP) announced that its highly promising anti-cancer drug, DS-8201, has a second pivotal trial, this time moving to Phase II for gastric cancer (GC). Earlier in the year, DS-8201 moved to Phase II for its key indication for metastatic breast cancer (mBC). Since publication of the disappointing clinical trial data for mirogabalin, DS-8201 has taken on massive importance for DSK. This is not just because it is now the drug with the most upside potential in DSK’s…

Daiichi Sankyo (4568) - DS-8201 Moves to Phase 2 for Gastric Cancer